Beyond Hypoglycemia: Glucagon as an Antidote
Most EMS providers know glucagon as the intramuscular treatment for hypoglycemia when IV access is not available. However, glucagon has an equally important role as an antidote for beta-blocker and calcium channel blocker overdoses. These overdoses can cause life-threatening bradycardia and hypotension that may not respond to conventional treatments like atropine and vasopressors.
Mechanism of Action in Toxicology
Glucagon works through a unique mechanism that bypasses the blocked beta receptors. It stimulates adenylate cyclase through glucagon receptors on cardiac myocytes, increasing intracellular cyclic AMP (cAMP) independent of the beta-adrenergic receptor. This increased cAMP enhances cardiac contractility (inotropy) and heart rate (chronotropy) despite the presence of beta-receptor blockade.
For calcium channel blocker toxicity, the mechanism is less well-established, but glucagon may partially overcome the negative inotropic and chronotropic effects through the same cAMP pathway.
Clinical Presentation of Beta-Blocker/CCB Overdose
Patients with significant beta-blocker or calcium channel blocker overdose may present with:
- Severe bradycardia (heart rate below 50 in symptomatic patients)
- Hypotension refractory to fluid boluses
- Altered mental status from poor cardiac output
- Heart block (first, second, or third degree)
- Cardiogenic shock
- Hypoglycemia (particularly with beta-blocker overdose)
Glucagon Dosing for Toxicology
The antidotal dose of glucagon is significantly higher than the hypoglycemia dose:
- Adult dose: 3 to 5 mg IV bolus over 1 to 2 minutes
- If effective: Follow with an infusion of 2 to 5 mg per hour
- Onset: 1 to 3 minutes IV
- Duration: 15 to 20 minutes (hence the need for a continuous infusion)
- Maximum bolus: 10 mg
The limited supply of glucagon on most ambulances (typically 1 to 2 mg) is a practical challenge. Communicate early with the receiving hospital so they can prepare additional glucagon and other treatments including high-dose insulin/euglycemic therapy, vasopressors, and potentially intralipid emulsion.
Practical Considerations
Glucagon commonly causes nausea and vomiting. Position the patient to protect the airway, and have suction ready. Monitor blood glucose after administration, as glucagon mobilizes glycogen stores and can cause transient hyperglycemia followed by hypoglycemia. Document the suspected ingestion, the time and dose of glucagon, and the clinical response including heart rate and blood pressure changes.